These are news releases that are related to our Investor efforts. Releases are listed in chronological order and are archived by year. Sign-up to receive news as it is released using the email and RSS tools below.
Feb 6, 2020
Sierra Oncology, Inc. (SRRA), a late-stage drug development company focused on the development and commercialization of momelotinib, a JAK1, JAK2 & ACVR1 inhibitor with a potentially...
Jan 22, 2020
- Preferred shares issued in recently completed $103M financing to convert to common shares - - Gilead to become shareholder in Sierra in accordance with amendment to Purchase Agreement -...
Dec 7, 2019Sierra Oncology Reports Decreased Transfusion Requirements for Patients Treated with Momelotinib Directly Compared to Ruxolitinib at ASH Annual Meeting
- New analyses of Phase 3 data highlighting momelotinib's meaningful anemia benefits in myelofibrosis presented in a poster at the 61st American Society of Hematology Annual Meeting - - Analyst &...
Dec 2, 2019
- Event featuring renowned myelofibrosis expert Dr. Ruben Mesa scheduled for 7:00 am ET on December 8th - - Data highlighting decreased transfusion requirements for patients treated with...
Nov 26, 2019Sierra Oncology Announces Closing of $103 Million Public Offering and Changes to its Board of Directors
Sierra Oncology, Inc. (Nasdaq: SRRA), a late-stage drug development company focused on the development and commercialization of momelotinib, a JAK1, JAK2 & ACVR1 inhibitor with a potentially...